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mIn conclusion it can be said that the necessity of systemic steroid therapy should be strongly considered in relation to the 
obtainable advantages and to the possibility of the colonization of bronchial tree by infectious agents (only 35% out of the 
patients with negative sputum culture reported frequent use of systemic steroids). Further studies will investigate the possible 
relation between systemic steroid therapy and different bacterial species. 
5. The treatment of community acquired pneumonia with fluoroquinolones 
G. DOUGLAS CAMPBELL AND GLENN TILLOTSON* 
LSU Medical Center, “Bayer Corporation, West Haven CT, USA. 
The combination of a /3-lactam and a macrolide is currently widely recommended treatment for community-acquired 
pneumonia (CAP) which is effective against a wide spectrum of organisms. However, because of a dramatic increase in the 
incidence of pneumococcal strains that are resistant to penicillin and other antimicrobials and because physicians cannot 
readily differentiate pneumonia caused by typical or atypical pathogens, alternative therapies are needed. 
Several new fluoroquinolones have been developed with enhanced Gram-positive and Gram-negative activities as well as a 
broader spectrum, including atypical pathogens. In this study, in vitro results and clinical efficacy and safety of the 
fluoroquinolones have been compared with that of the currently accepted therapy for CAP, based on published information. 
In vitro, moxifloxacin and trovafloxacin were the most potent fluoroquinolones with MIC90 0.125 mg/L against S. pneumoniae. 
The clinical cure rate was highest with moxifloxacin, levofloxacin and clarithromycin, reaching cures 295% of patients at the 
end of treatment and maintaining these results at follow-up. The eradication rates confirmed the potency of moxifloxacin, 
which successfully eradicated Gram-positive and Gram-negative bacilli as well as atypical pathogens. The safety profiles of 
moxifloxacin and levofloxacin were good and comparable, while grepafloxacin had a significant incidence of taste perversion 
(26%) and nausea (13.8%) and sparfloxacin exhibited photosensitivity reactions (2.4%). 
Most of the newer fluoroquinolones have an improved efficacy and safety profile compared to the earlier drugs. Overall, 
moxifloxacin appears to be a promising alternative to existing therapy with the highest in vitro potency correlating well with 
excellent clinical efficacy and good safety. 
6. Duration of hospitalization of patients with pneumonia in relation to the existence 
of underlying diseases 
G. CHRYSOFAKIS, H. LAMBRAKIS, N. TZANAKIS, D. BOUROS, N. M. SIAFAKAS 
Dept. of Thoracic Medicine, Medical School University of Crete, Greece 
The duration of hospitalization of patients with pneumonia may be different in patients with or without underlying diseases. 
The aim of this study was to investigate whether hospitalization time is different between patients with pneumonia who have 
or do not have underlying comorbidity. 
We studied 70 patients with pneumonia who were hospitalized during the years 1997-1998. Thirty of the patients (18 were 
male, smokers and 12 female non-smokers), mean (SD) age 35*10 years had no underlying disease. The other 40 patients 
(32 male smokers and 8 female non-smokers ), mean (SD) age 60*5 years, had underlying disease: COPD (n= 15),coronary 
artery disease (n= lo), diabetes mellitus (n= 12) and alcoholism (n=3) . 
In the first group, the average hospitalization time was 5?2 days, whereas in the second, 9?2 days (P=O.O27).This 
difference could not be attributed to differences in treatment. The mean age of the groups was significantly different 
(P=O.O12). 
Our results suggest that the existence of underlying diseases increases the hospitalization time of patients with community- 
acquired pneumonia. 
7. Pharrnacoeconomical analysis of AECB treatment using a computerised case report 
form 
S. DAMATO, R. RACCANELLI, F. BLASI, L. CHIESA, V. FRIGO, G. NEGRETTO, C. RAMPOLDI, 
F. RODI AND l? TARSIA 
Pulmonary Rehabilitation Unit (Seregno, MI) - Universities of Milano and Milano Bicocca 
In an outpatient setting we used a computerised case report form also to classify exacerbations of COPD (AECB) according 
to Anthonisen criteria (AcI, AcII, AcIII) and to calculate costs of different antibiotic treatments (ATR). Between 9/98 and 
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TABLE 
NS (1) SS NS (2) SS NS (3) SS 
No Antibiotics 13.1% 9.8% 0.0% 0.0% -13.1 -9.8 
Oral Synthetic Penicillin 
Oral Cephalosporin (CE) 
Parenteral Cephalosporin 
P-Lactam. Resist. Oral CE 
Quinolone 
Macrolide 
10.7% 11.8% 5.5% 7.5% -5.2 -4.3 
48% 3.9% 6.3% 2.9% 1.5 -1.0 
4.8% 9.8% 25.0% 41.4% 20.2 31.6 
14.3% 3.9% 10.2% 18% -4.1 1.6 
23.8% 49.0% 31.2% 41.4% 7.4 -7.6 
28.6% 11.8% 35.8% 5.0% -6.9 -6.8 
8/99 we performed 704 examinations (exams) on 390 COPD patients (age 66.4? 3 1, M 275). 180 exams of patients with FEVl 
<50%pred were classified as severe (SS); the remaining 524 exams were classified as NS. Among NS exams we identified 84 
AECB (age 64.3?21, AcI 29.8%, AcII 42.9%, AcIII 27.4%) whereas 51 AECB were recorded among SS exams (age 
67.4+37,AcI 42.9%, AcII 43.1%, AcIII 11.8%). Decisions regarding whether and how to treat were left to visiting physicians. 
The table shows for each ATR and for each severity group: (1) the % of AECB, (2) the % of total costs attributable to ATR 
and (3) the difference between the two above percentages. In deciding whether and how to treat AECB, adherence to 
international guidelines was not complete. The overall costs of ATR was 5,861 US$. ATR costs for AECB in COPD-SS were 
60 US$, whereas for NS patients were 32 US$. The greater cost for SS AECB is mainly attributable to use of the parenteral 
antibiotics. 
8. AECB in an out-patient pulmonary setting and smoking habit 
S. DAMATO, R. RACCANELLI, C. RAMPOLDI, T. CAMNASIO, L. CHIESA, V. FRIGO, 
G. NEGRETTO AND F. RODI 
Pulmonary Rehabilitation Unit (Seregno), University of Milano-Bicocca, Italy 
In 555 COPD patients we performed 970 examinations (exams) over a one year period. 186 exams (age 65.5+21, males 125) 
have been classified as exacerbations (AECB), according to Anthonisen: 41% in ex-smokers (EX), 29% in non smokers (N) 
and 30% in smokers (S). We have subdivided the AECB exams also in relation to seasons (autumn-winter=AW, spring- 
summer=SS), as shown in the table. 
TABLE 
EX N S 
AW 51.3% 57.4% 64.2% 
ss 48.7% 42.6% 35.8% 
Actual or former smoking habit is related with higher prevalence of AECB. Only in ex smokers is the prevalence of EACB 
almost the same during the year. 
9. Lower respiratory infections: observational study in Genoa 
A. DE MARIA, M. BERARDI, L. FERRERA, I? ORSI, I. STARA AND G. W. CANONICA 
Allergy and Respiratory Diseases, Dept. of Internal Medicine, University of Genoa, Italy 
Background: lower respiratory tract infections (LRTI) are responsible for significant morbility, mortality and costs in all 
developed countries. To provide improved care for patients with LRTI, international and local guidelines for clinical and 
antibiotic management have been issued over the years. 
